Clinical Trials

90 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT03223779 2026-03-12

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Phase 1/2 Completed

52 enrolled

Colorectal Neoplasms

NCT07011550 2026-03-11

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

7 enrolled

Microsatellite-stable Colorectal Cancer

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

572 enrolled

Stomach Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Colorectal Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

23 enrolled 12 charts

Stomach Neoplasms

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT06356311 2026-02-27

TroFuse-015

450 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Adenocarcinoma Of Esophagus

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT07146646 2026-02-19

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

27 enrolled

Phase 3 Active not recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05198934 2026-02-06

CodeBreak300

160 enrolled 1 FDA

Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Phase NA Not yet recruiting

Colonic Neoplasms

NCT07371871 2026-01-28

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

30 enrolled

Advanced Gastric Cancer

NCT04457297 2026-01-21

ALTAIR

Phase 3 Completed

243 enrolled 13 charts

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

100 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04564898 2026-01-08

TriComB

48 enrolled

Colorectal Cancer Metastatic

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT07280377 2025-12-12

GOBLET

Phase 1/2 Recruiting

122 enrolled

Anal Cancer Metastatic

NCT04417699 2025-12-10

SHORT

13 enrolled 12 charts

Rectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT05839951 2025-11-12

STAR-T

Completed

818 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT05029882 2025-10-29

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

520 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04104139 2025-10-27

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Phase 1 Active not recruiting

19 enrolled

Rectal Neoplasms

NCT07212933 2025-10-08

RAK in GC

90 enrolled

Stomach Neoplasms

NCT05064059 2025-09-17

MK-4280A-007

Phase 3 Completed

441 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

57 enrolled

Colorectal Neoplasms

NCT06614192 2025-08-26

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Phase 3 Recruiting

460 enrolled

Colorectal Neoplasms

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma

NCT05328908 2025-08-13

RELATIVITY-123

Phase 3 Terminated

770 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07085169 2025-07-25

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

50 enrolled

Colonic Neoplasms

NCT04923529 2025-07-18

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

28 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms

NCT06199973 2025-07-17

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

130 enrolled

Phase 2 Not yet recruiting

Advanced Colorectal Cancer

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Phase 1/2 Active not recruiting

Neutropenia, Colorectal Neoplasms

NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

75 enrolled

Phase 3 Not yet recruiting

Gastric and Gastroesophageal Junction Adenocarcinoma

NCT06850090 2025-06-25

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

210 enrolled

Rectal Neoplasms

NCT07012954 2025-06-24

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Phase 1/2 Recruiting

64 enrolled

Colorectal Cancer Metastatic

NCT05854498 2025-06-12

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

25 enrolled

Colorectal Neoplasms

NCT05481463 2025-05-28

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

22 enrolled

Pancreatic Neoplasms

NCT05848739 2025-05-11

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1 Recruiting

130 enrolled

Colonic Neoplasms

NCT05965531 2025-04-29

TASLARC

65 enrolled

Rectal Neoplasms

NCT04920032 2025-04-08

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Phase 1 Recruiting

22 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT06882915 2025-03-19

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

20 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

64 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT04701476 2024-11-22

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

110 enrolled

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

50 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT05476796 2024-10-24

LOGICAN

118 enrolled